| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| topiramate | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 18/10/2024 |
| topiramate | Tablet, film coated | 100 mg | Anticipated | Available | Manufacturing | 18/10/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Anticipated | Available | Unexpected increase in consumer demand | 18/10/2024 |
| tamsulosin hydrochloride~dutasteride | Capsule, modified release | 400 microgram~500 microgram | Current | Limited Availability | Manufacturing | 18/10/2024 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| oxycodone hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Commercial Changes / Commercial viability | 18/10/2024 |
| fenofibrate | Tablet | 48 mg | Resolved | Available | Manufacturing | 18/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 18/10/2024 |
| lacosamide | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 18/10/2024 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 18/10/2024 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 18/10/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| trimethoprim | Tablet, uncoated | 300 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 18/10/2024 |
| indometacin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 18/10/2024 |
| octreotide | Injection, solution | 50 microgram/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 18/10/2024 |
| clonazepam | Tablet, uncoated | .5 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| clonazepam | Tablet, uncoated | 2 mg | Current | Limited Availability | Manufacturing | 18/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 18/10/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 18/10/2024 |
| topiramate | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 17/10/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Resolved | Available | Manufacturing | 17/10/2024 |
| mitomycin | Injection, powder for | 20 mg | Current | Unavailable | Manufacturing | 17/10/2024 |
| azacitidine | Injection, powder for | 100 mg | Current | Unavailable | Manufacturing | 17/10/2024 |
| irbesartan | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 17/10/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 17/10/2024 |
| lisdexamfetamine dimesilate | Capsule, hard | 60 mg | Resolved | Available | Unexpected increase in consumer demand | 17/10/2024 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 17/10/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 17/10/2024 |
| daptomycin | Injection, powder for | 500 mg | Current | Unavailable | Commercial Changes / Commercial viability | 17/10/2024 |
| tamoxifen citrate | Tablet | 30.34 mg | Current | Limited Availability | Manufacturing | 17/10/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 16/10/2024 |
| risperidone | Tablet, film coated | 4 mg | Anticipated | Available | Manufacturing | 16/10/2024 |
| rocuronium bromide | Injection, solution | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/10/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 10.9 mg~10 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| entecavir | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 25 mg~300 mg | Anticipated | Available | Manufacturing | 16/10/2024 |
| tadalafil | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 16/10/2024 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Anticipated | Available | Manufacturing | 16/10/2024 |
| linezolid | Tablet, film coated | 600 mg | Resolved | Available | Unexpected increase in consumer demand | 16/10/2024 |
| latanoprost~timolol maleate | Eye Drops, solution | .05 mg/mL~6.83 mg/mL | Anticipated | Available | Manufacturing | 16/10/2024 |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 16/10/2024 |
| bendamustine hydrochloride monohydrate | Injection, powder for | 100 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2024 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.94 mg~40 mg | Current | Unavailable | Unexpected increase in consumer demand | 16/10/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| daptomycin | Inhalation, powder for | 350 mg | Anticipated | Available | Manufacturing | 16/10/2024 |
| enoxaparin sodium | Injection, solution | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Current | Unavailable | Manufacturing | 16/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.8 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| nizatidine | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| Tenecteplase | Injection, powder for | 50 mg | Resolved | Available | Unexpected increase in consumer demand | 16/10/2024 |
| sodium pertechnetate(99mTc) | Injection | 370 GBq | Resolved | Available | Manufacturing | 16/10/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Anticipated | Available | Manufacturing | 16/10/2024 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/10/2024 |
| nizatidine | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 16/10/2024 |
| acetylcholine chloride | Solution, powder for irrigation | 10 mg/mL | Current | Unavailable | Manufacturing | 15/10/2024 |
| daunorubicin | Injection, solution | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/10/2024 |
| anidulafungin | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 15/10/2024 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 15/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 15/10/2024 |
| Digoxinspecific antibody fragment F(ab) (Ovine) | Injection, powder for | 40 mg | Anticipated | Available | Manufacturing | 15/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 15/10/2024 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 15/10/2024 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 15/10/2024 |
| Follitropin alfa | Injection, solution | 75 IU | Current | Limited Availability | Manufacturing | 15/10/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Resolved | Available | Manufacturing | 15/10/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 15/10/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 15/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Unexpected increase in consumer demand | 15/10/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| prasugrel | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| prasugrel | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 15/10/2024 |
| estradiol | Drug delivery system, transdermal | .585 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| estradiol | Drug delivery system, transdermal | 1.17 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 15/10/2024 |
| pegcetacoplan | Injection, solution | 1080 mg | Resolved | Available | Manufacturing | 15/10/2024 |
| rocuronium bromide | Injection, solution | 10 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/10/2024 |
| estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~2.7 mg | Resolved | Available | Manufacturing | 15/10/2024 |
| pimecrolimus | Cream | 10 mg/g | Resolved | Available | Manufacturing | 15/10/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Anticipated | Available | Unexpected increase in consumer demand | 15/10/2024 |
| griseofulvin | Tablet, uncoated | 125 mg | Resolved | Available | Manufacturing | 14/10/2024 |
| olsalazine sodium | Capsule | 250 mg | Current | Unavailable | Manufacturing | 14/10/2024 |
| iopromide | Injection, solution | 498.72 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 14/10/2024 |
| telmisartan~hydrochlorothiazide | Tablet, film coated | 80 mg~12.5 mg | Current | Limited Availability | Manufacturing | 14/10/2024 |
| esomeprazole magnesium dihydrate | Tablet, enteric coated | 21.75 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 14/10/2024 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 14/10/2024 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Anticipated | Available | Unexpected increase in consumer demand | 14/10/2024 |
| thiotepa | Injection, powder for | 15 mg | Anticipated | Available | Commercial Changes / Commercial viability | 14/10/2024 |
| betahistine dihydrochloride | Tablet | 16 mg | Resolved | Available | Unexpected increase in consumer demand | 14/10/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 14/10/2024 |
| olsalazine sodium | Tablet, uncoated | 500 mg | Current | Unavailable | Manufacturing | 14/10/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Current | Limited Availability | Manufacturing | 11/10/2024 |
| primidone | Tablet, uncoated | 250 mg | Current | Limited Availability | Manufacturing | 11/10/2024 |
| neostigmine methylsulfate | Injection, solution | 2.5 mg | Anticipated | Available | Manufacturing | 11/10/2024 |
| tadalafil | Tablet | 5 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 11/10/2024 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 11/10/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Current | Limited Availability | Manufacturing | 11/10/2024 |
| midazolam | Injection, solution | 5 mg/mL | Resolved | Available | Manufacturing | 11/10/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Anticipated | Available | Manufacturing | 10/10/2024 |
| bisoprolol fumarate | Tablet | 5 mg | Current | Unavailable | Manufacturing | 10/10/2024 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Anticipated | Available | Manufacturing | 10/10/2024 |
2024年10月23日